The subtype‐specific risk factors and genetic susceptibility would provide several preliminary insights into the established prevention and therapeutic strategy and trigger more investigations of HER2‐low and HER2‐zero BC in the future, especially for HR‐negative BC.40 The gene discussed is ERBB2; the disease is breast cancer.